Medical Crossfire : Translating Recent Data Into Informed Sequencing Decisions in Advanced Non-Small Cell Lung Cancer
WebcastFaculty
OVERVIEW
Medical Crossfire : Translating Recent Data Into Informed Sequencing Decisions in Advanced Non-Small Cell Lung Cancer is organized by Physicians Education Resource, LLC (PER) and will be held during Mar 31, 2017 - Mar 31, 2018.
The target audience for this medical event is oncologists, nurse practitioners, nurses, and physician assistants involved in the treatment and management of patients with lung cancers. Pharmacists, researchers, fellows, and other healthcare professionals interested in the treatment of lung cancers may also participate. This CME Conference has been approved for a maximum of 2.0 AMA PRA Category 1 Credits.
Conference Objectives :
• Review key concepts that inform front-line clinical decision making in advanced NSCLC in the context of recent clinical trial evidence.
• Assess current and emerging testing methods to identify tumor characteristics that allow for personalized treatment strategies for patients with lung cancer.
• Discuss methods to monitor response in patients receiving treatment for advanced NSCLC.
• Review clinical trial evidence in NSCLC that informs decisions on the timing of treatment switching beyond disease progression.
• Summarize strategies to proactively plan for and manage treatment-related adverse events in patients with advanced NSCLC.
Additional details will be posted as soon as they are available.
The target audience for this medical event is oncologists, nurse practitioners, nurses, and physician assistants involved in the treatment and management of patients with lung cancers. Pharmacists, researchers, fellows, and other healthcare professionals interested in the treatment of lung cancers may also participate. This CME Conference has been approved for a maximum of 2.0 AMA PRA Category 1 Credits.
Conference Objectives :
• Review key concepts that inform front-line clinical decision making in advanced NSCLC in the context of recent clinical trial evidence.
• Assess current and emerging testing methods to identify tumor characteristics that allow for personalized treatment strategies for patients with lung cancer.
• Discuss methods to monitor response in patients receiving treatment for advanced NSCLC.
• Review clinical trial evidence in NSCLC that informs decisions on the timing of treatment switching beyond disease progression.
• Summarize strategies to proactively plan for and manage treatment-related adverse events in patients with advanced NSCLC.
Additional details will be posted as soon as they are available.
FACULTY
SPECIALITIES
Oncology
Quick Links